CYP2D6HGNC PubMedDose recommendationNew recommendation

Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use

Baune BT — Pharmacogenomics 2026 · June 2026

Relevance score

7/10

Disease / domain

Major depressive disorder — pharmacogenetics-guided antidepressant prescribing

Gene–drug pair / mechanism

Evidence review and clinical roadmap for *CYP2D6*, *CYP2C19*, and *CYP2B6* use in antidepressant treatment stratification

Summary

A comprehensive review evaluates the evidence and limits of pharmacogenomics for stratified antidepressant prescribing in major depressive disorder (MDD). Genes CYP2D6, CYP2C19, and CYP2B6 are validated as actionable (CPIC recommendations), while SLC6A4 and HTR2A are confirmed non-actionable. Meta-analyses show moderate response gains in enriched subgroups (treatment-failed patients, severe MDD). The author proposes a 4-step roadmap for clinical integration.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Analysis

The clarification between actionable PGx genes (CYP2D6/CYP2C19/CYP2B6) and non-actionable ones (SLC6A4/HTR2A) in depression is an important contribution of this article. The proposed roadmap is pragmatic and applicable in a psychiatric prescribing context. Worth recommending to psychiatrists and neurologists interfacing with pharmacogenetics consultations.

Why this score?

Clinical impact: 2/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 1/1 → Total: 7/10

Keywords

CYP2D6CYP2C19antidepressantsmajor depressive disorderCPIC